Location History:
- Vallejo, CA (US) (2009 - 2012)
- Albany, CA (US) (2007 - 2017)
Company Filing History:
6 out of 245 
1 out of 3 
1 out of 832,961 Years Active: 2007-2017
Title: The Innovative Contributions of Inventor Ying Lian in HIV Research
Introduction
Ying Lian, an accomplished inventor based in Albany, CA, has made significant strides in the field of HIV research. With a total of seven patents to his name, he has developed groundbreaking technologies aimed at enhancing the understanding and treatment of the HIV virus.
Latest Patents
Among Ying Lian's latest innovations are two key patents focusing on HIV-1 South African subtype C env proteins. The first patent describes polynucleotides encoding immunogenic HIV polypeptides. This invention outlines various applications, including immunization strategies, the generation of packaging cell lines, and their role in producing HIV polypeptides. The patent emphasizes the utility of these polynucleotides in formulating immunogenic compositions that can serve crucial functions in HIV research.
His second noteworthy patent concerns the expression of HIV polypeptides in multiple cell types, which include mammalian, insect, and plant cells. This patent offers synthetic expression cassettes encoding HIV Gag-containing polypeptides, highlighting applications in DNA immunization, the generation of packaging cell lines, and the production of critical proteins. Through these advancements, methods for producing Virus-Like Particles (VLPs) are detailed, showcasing their potential as vehicles for antigen presentation and stimulating immune responses in subjects.
Career Highlights
Throughout his career, Ying Lian has worked with notable organizations, including Novartis Vaccines & Diagnostics GmbH. His work has consistently focused on innovative solutions to combat HIV, positioning him as a leader in medical research. His extensive contributions to vaccine development and immunology have led to significant advancements in therapeutic approaches to the virus.
Collaborations
Ying Lian has collaborated with esteemed colleagues in the field, including Jan Zur Megede and Susan Barnett. These partnerships have fostered a collaborative environment that promotes the exchange of ideas and methodologies, enhancing the overall impact of their research initiatives.
Conclusion
Ying Lian's contributions through his patents reflect a deep commitment to combating HIV and advancing medical science. His innovative approaches and collaborations with leading researchers underscore the importance of continuous development in the realm of infectious diseases. As research in this area progresses, the impact of Ying Lian's work will likely resonate in future therapies and vaccine strategies.